相似文献
1
Optimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy.
Gut Microbes. 2016;7(2):171-7. doi: 10.1080/19490976.2016.1155021.
2
Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy.
mBio. 2015 Apr 14;6(2):e00254-15. doi: 10.1128/mBio.00254-15.
3
Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models.
J Gene Med. 2008 Jun;10(6):690-701. doi: 10.1002/jgm.1191.
4
Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.
BMC Cancer. 2005 Feb 9;5:15. doi: 10.1186/1471-2407-5-15.
5
Refined live attenuated Salmonella enterica serovar Typhimurium and Enteritidis vaccines mediate homologous and heterologous serogroup protection in mice.
Infect Immun. 2015 Dec;83(12):4504-12. doi: 10.1128/IAI.00924-15. Epub 2015 Sep 8.
6
Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
Cancer Lett. 2020 Jan 28;469:102-110. doi: 10.1016/j.canlet.2019.10.033. Epub 2019 Oct 24.
7
Local application of bacteria improves safety of Salmonella -mediated tumor therapy and retains advantages of systemic infection.
Oncotarget. 2017 Jul 25;8(30):49988-50001. doi: 10.18632/oncotarget.18392.
8
Attenuation of Salmonella enterica Serovar Typhimurium by altering biological functions of murein lipoprotein and lipopolysaccharide.
Infect Immun. 2005 Dec;73(12):8433-6. doi: 10.1128/IAI.73.12.8433-8436.2005.
9
Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β.
Theranostics. 2015 Oct 6;5(12):1328-42. doi: 10.7150/thno.11432. eCollection 2015.
10
Characterization of a highly attenuated Salmonella enterica serovar Typhimurium mutant strain.
J Microbiol Immunol Infect. 2002 Dec;35(4):229-35.
引用本文的文献
1
Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling.
Cell Commun Signal. 2024 Oct 16;22(1):500. doi: 10.1186/s12964-024-01874-6.
2
Attenuated Salmonella typhimurium L forms suppress tumor growth and promote apoptosis in murine ovarian tumors.
Sci Rep. 2024 Jul 11;14(1):16045. doi: 10.1038/s41598-024-66898-x.
3
and outer membrane vesicles are current and future options for cancer treatment.
Front Cell Infect Microbiol. 2023 Dec 5;13:1293351. doi: 10.3389/fcimb.2023.1293351. eCollection 2023.
4
MEK inhibitors increase the mortality rate in mice with LPS-induced inflammation through IL-12-NO signaling.
Cell Death Discov. 2023 Oct 13;9(1):374. doi: 10.1038/s41420-023-01674-w.
5
AI-2 quorum sensing controlled delivery of cytolysin-A by tryptophan auxotrophic low-endotoxic Salmonella and its anticancer effects in CT26 mice with colon cancer.
J Adv Res. 2024 Jul;61:83-100. doi: 10.1016/j.jare.2023.09.003. Epub 2023 Sep 7.
6
Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies.
Front Immunol. 2023 Aug 3;14:1140463. doi: 10.3389/fimmu.2023.1140463. eCollection 2023.
7
Bacterial-Mediated Tumor Therapy: Old Treatment in a New Context.
Adv Sci (Weinh). 2023 Apr;10(12):e2205641. doi: 10.1002/advs.202205641. Epub 2023 Mar 12.
8
-mediated blood‒brain barrier penetration, tumor homing and tumor microenvironment regulation for enhanced chemo/bacterial glioma therapy.
Acta Pharm Sin B. 2023 Feb;13(2):819-833. doi: 10.1016/j.apsb.2022.09.016. Epub 2022 Sep 25.
9
may support cancer treatment: a review.
Acta Biochim Biophys Sin (Shanghai). 2023 Feb 25;55(3):331-342. doi: 10.3724/abbs.2023007.
10
Recent advances in bacteria-mediated cancer therapy.
Front Bioeng Biotechnol. 2022 Oct 12;10:1026248. doi: 10.3389/fbioe.2022.1026248. eCollection 2022.
本文引用的文献
1
Rescuing chemotaxis of the anticancer agent Salmonella enterica serovar Typhimurium VNP20009.
J Biotechnol. 2015 Oct 10;211:117-20. doi: 10.1016/j.jbiotec.2015.07.010. Epub 2015 Jul 19.
2
Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy.
mBio. 2015 Apr 14;6(2):e00254-15. doi: 10.1128/mBio.00254-15.
3
Recognition of lipid A variants by the TLR4-MD-2 receptor complex.
Front Cell Infect Microbiol. 2013 Feb 12;3:3. doi: 10.3389/fcimb.2013.00003. eCollection 2013.
4
Modulating the innate immune response by combinatorial engineering of endotoxin.
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1464-9. doi: 10.1073/pnas.1218080110. Epub 2013 Jan 7.
5
New technologies in developing recombinant attenuated Salmonella vaccine vectors.
Microb Pathog. 2013 May;58:17-28. doi: 10.1016/j.micpath.2012.10.006. Epub 2012 Nov 8.
6
Turning self-destructing Salmonella into a universal DNA vaccine delivery platform.
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19414-9. doi: 10.1073/pnas.1217554109. Epub 2012 Nov 5.
7
Comparative genome analysis of the high pathogenicity Salmonella Typhimurium strain UK-1.
PLoS One. 2012;7(7):e40645. doi: 10.1371/journal.pone.0040645. Epub 2012 Jul 6.
8
Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.
J Immunol. 2011 Jul 1;187(1):412-23. doi: 10.4049/jimmunol.1100339. Epub 2011 Jun 1.
9
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
10
2011: the immune hallmarks of cancer.
Cancer Immunol Immunother. 2011 Mar;60(3):319-26. doi: 10.1007/s00262-010-0968-0. Epub 2011 Jan 26.
Zotero 插件